BAFNAPH — BAFNA Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for BAFNA Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	712	851	1,154	1,526	1,459
Cost of Revenue
Gross Profit	258	339	389	497	428
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	654	808	1,035	1,454	1,396
Operating Profit	58.2	43.1	119	71.3	62.9
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	58.3	52.2	116	73.5	63
Provision for Income Taxes
Net Income After Taxes	58.3	52.2	113	73.5	41.5
Net Income Before Extraordinary Items
Net Income	58.3	52.2	113	73.5	41.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	58.3	52.2	113	73.5	41.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.46	3.1	4.78	3.08	1.76